Commentary

D1.450 Overview

Corporate tax
Corporate tax | Commentary

D1.450 Overview

Corporate tax | Commentary

Vaccine research relief

D1.450 Overview

The provisions in this article apply to large companies (for expenditure incurred before 1 April 2017) and SMEs (for expenditure incurred before 1 April 2012).

For expenditure incurred on or after 22 April 2003, vaccine research relief (VRR)1 is available where the following conditions are met2:

  1.  

    (a)     the expenditure is qualifying R&D expenditure (see D1.452) relating to:

    1.  

      (1)     vaccines or medicines for the prevention or treatment of tuberculosis (TB) or malaria;

    2.  

      (2)     vaccines for the prevention of human immunodeficiency virus (HIV) infection; and

    3.  

      (3)     vaccines or medicines for the prevention of the onset of

To continue reading
View the latest version of this document, as well as thousands of others like it, sign in to TolleyLibrary or register for a free trial